122 related articles for article (PubMed ID: 13129567)
1. The discovery of BMS-275183: an orally efficacious novel taxane.
Mastalerz H; Cook D; Fairchild CR; Hansel S; Johnson W; Kadow JF; Long BH; Rose WC; Tarrant J; Wu MJ; Xue MQ; Zhang G; Zoeckler M; Vyas DM
Bioorg Med Chem; 2003 Oct; 11(20):4315-23. PubMed ID: 13129567
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of C-7, C-9 and C-10 modified taxane analogues from 1-deoxybaccatin VI.
Xie C; Cui Y; Li L; Zhang M; Liu H; Lin H
Bioorg Med Chem; 2020 Nov; 28(21):115736. PubMed ID: 33065439
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
4. IDN 5390: a new concept in taxane development.
Taraboletti G; Micheletti G; Giavazzi R; Riva A
Anticancer Drugs; 2003 Apr; 14(4):255-8. PubMed ID: 12679728
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel.
Liu Z; Zheng X; Lv J; Zhou X; Wang Q; Wen X; Liu H; Jiang J; Wang L
Phytomedicine; 2015 May; 22(5):573-8. PubMed ID: 25981924
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
[TBL] [Abstract][Full Text] [Related]
7. Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.
Xiao X; Wu J; Trigili C; Chen H; Chu JW; Zhao Y; Lu P; Sheng L; Li Y; Sharom FJ; Barasoain I; Diaz JF; Fang WS
Bioorg Med Chem Lett; 2011 Aug; 21(16):4852-6. PubMed ID: 21764308
[TBL] [Abstract][Full Text] [Related]
8. Oral efficacy and bioavailability of a novel taxane.
Polizzi D; Pratesi G; Monestiroli S; Tortoreto M; Zunino F; Bombardelli E; Riva A; Morazzoni P; Colombo T; D'Incalci M; Zucchetti M
Clin Cancer Res; 2000 May; 6(5):2070-4. PubMed ID: 10815934
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of BMS-275183, an orally active taxane.
Rose WC; Long BH; Fairchild CR; Lee FY; Kadow JF
Clin Cancer Res; 2001 Jul; 7(7):2016-21. PubMed ID: 11448919
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390.
Barboni L; Ballini R; Giarlo G; Appendino G; Fontana G; Bombardelli E
Bioorg Med Chem Lett; 2005 Dec; 15(23):5182-6. PubMed ID: 16183281
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of C-13, C-14 modified taxane analogues from 1-deoxybaccatin VI.
Tang P; Lin HX; Yuan TH; Cui YM
Nat Prod Res; 2019 Dec; 33(24):3478-3484. PubMed ID: 29897250
[TBL] [Abstract][Full Text] [Related]
13. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of macrocyclic taxane analogues.
Tarrant JG; Cook D; Fairchild C; Kadow JF; Long BH; Rose WC; Vyas D
Bioorg Med Chem Lett; 2004 May; 14(10):2555-8. PubMed ID: 15109650
[TBL] [Abstract][Full Text] [Related]
15. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
17. Novel taxane derivatives from Taxus wallichiana with high anticancer potency on tumor cells.
Wang Y; Wang J; Wang H; Ye W
Chem Biol Drug Des; 2016 Oct; 88(4):556-61. PubMed ID: 27153813
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183.
Bröker LE; Valdivieso M; Pilat MJ; Deluca P; Zhou X; Parker S; Giaccone G; Lorusso PM
Clin Cancer Res; 2008 Jul; 14(13):4186-91. PubMed ID: 18593998
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of ring C-secotaxoids. 1. Acylative modifications.
Appendino G; Bettoni P; Noncovich A; Sterner O; Fontana G; Bombardelli E; Pera P; Bernacki RJ
J Nat Prod; 2004 Feb; 67(2):184-8. PubMed ID: 14987056
[TBL] [Abstract][Full Text] [Related]
20. CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183).
Zhang D; Ly VT; Lago M; Tian Y; Gan J; Humphreys WG; Cömezoglu SN
Drug Metab Dispos; 2009 Apr; 37(4):710-8. PubMed ID: 19158314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
